Company Filing History:
Years Active: 2015-2016
Title: Nahm-Ju Kim: Innovator in Monoclonal Antibody Research
Introduction
Nahm-Ju Kim is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, Kim's work focuses on innovative solutions for cancer treatment.
Latest Patents
One of Kim's latest patents is titled "Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof." This invention pertains to human monoclonal antibodies that neutralize vascular endothelial growth factor receptors. Specifically, it involves human ScFv molecules that inhibit angiogenesis and can be used in cancer treatment. The disclosed monoclonal antibody demonstrates superior neutralizing ability in living cells compared to commercially available alternatives. It effectively neutralizes vascular endothelial growth factor receptors in humans, mice, and rats, making it a promising candidate for anticancer studies.
Career Highlights
Nahm-Ju Kim is currently associated with Pharmabcine Inc., where he continues to advance his research in monoclonal antibodies. His work has garnered attention for its potential impact on cancer therapies and treatment methodologies.
Collaborations
Kim has collaborated with notable colleagues, including Jin-San Yoo and Weon-Sup Lee. These partnerships have contributed to the development and refinement of his innovative research.
Conclusion
Nahm-Ju Kim is a key figure in the field of monoclonal antibody research, with a focus on cancer treatment. His inventions and collaborations highlight his commitment to advancing medical science and improving patient outcomes.